Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker–based immunotherapy

Immune checkpoint blockers (ICBs) have shown great promise at harnessing immune system to combat cancer. However, only a fraction of patients can directly benefit from the anti–programmed cell death protein 1 (aPD1) therapy, and the treatment often leads to immune-related adverse effects. In this co...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Feihu, Xu, Dongqing, Su, Hao, Zhang, Weijie, Sun, Xuanrong, Monroe, Maya K., Chakroun, Rami W., Wang, Zongyuan, Dai, Wenbing, Oh, Richard, Wang, Han, Fan, Qin, Wan, Fengyi, Cui, Honggang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239700/
https://www.ncbi.nlm.nih.gov/pubmed/32490201
http://dx.doi.org/10.1126/sciadv.aaz8985

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239700/
https://www.ncbi.nlm.nih.gov/pubmed/32490201
http://dx.doi.org/10.1126/sciadv.aaz8985

Ejemplares similares